Trial
NCT05338450
Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Amsterdam UMC, location VUmc
Collaborators
—
Condition
Multiple Sclerosis
Intervention
Clemastine Fumarate
Why stopped
In line with the study protocol, due to slow recruitment, a futility analysis has been performed in the first quarter of 2025 by an independent statistician. The result of the analysis was restricted to a "no-go".
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-06